Previous close | 60.37 |
Open | 60.24 |
Bid | 58.65 x 800 |
Ask | 61.07 x 2200 |
Day's range | 58.76 - 60.38 |
52-week range | 58.54 - 86.29 |
Volume | |
Avg. volume | 1,620,463 |
Market cap | 13.179B |
Beta (5Y monthly) | 0.69 |
PE ratio (TTM) | 36.30 |
EPS (TTM) | 1.62 |
Earnings date | 30 Oct 2023 - 03 Nov 2023 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 83.06 |
The US Food and Drug Administration (FDA) has approved GlaxoSmithKline's (NYSE:GSK) novel treatment, Ojjaara (momelotinib), for adults with intermediate- or high-risk myelofibrosis and anemia. This announcement comes after a three-month delay due to the need for additional data review.
Incyte (INCY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
WILMINGTON, Del., August 22, 2023--Incyte (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of September: